David Risinger
Stock Analyst at Leerink Partners
(4.55)
# 194
Out of 4,784 analysts
168
Total ratings
65.17%
Success rate
14.43%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $637.36 | +30.85% | 8 | Feb 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $182 → $169 | $163.71 | +3.23% | 3 | Jan 23, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $205.29 | +0.35% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $60.02 | +21.63% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $18.65 | +269.97% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $6.49 | +146.53% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $12.50 | +252.00% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $69.46 | +120.27% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $9.23 | +8.34% | 3 | Aug 6, 2024 | |
| HLVX HilleVax | Downgrades: Market Perform | $28 → $2 | $1.59 | +25.79% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $18.95 | +148.02% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $306.95 | +3.60% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $14.59 | -24.61% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $822.51 | -44.32% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $63.84 | -34.21% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $374 → $365 | $492.69 | -25.92% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $111.79 | -18.60% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $25.21 | +90.40% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $10.38 | -3.66% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $28.98 | -65.49% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $14.51 | +155.00% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $122.92 | +43.18% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $8.68 | +84.33% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $28.06 | +60.37% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.48 | +440.12% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $10.41 | +293.85% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $163.11 | +6.68% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $31.37 | +62.58% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $15.08 | -46.95% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $89.23 | -0.26% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $8.28 | -63.77% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $33.21 | -51.82% | 9 | Apr 2, 2020 | |
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $637.36
Upside: +30.85%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $182 → $169
Current: $163.71
Upside: +3.23%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $205.29
Upside: +0.35%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $60.02
Upside: +21.63%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $18.65
Upside: +269.97%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $6.49
Upside: +146.53%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $12.50
Upside: +252.00%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $69.46
Upside: +120.27%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $9.23
Upside: +8.34%
HilleVax
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.59
Upside: +25.79%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $18.95
Upside: +148.02%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $306.95
Upside: +3.60%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $14.59
Upside: -24.61%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $822.51
Upside: -44.32%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $63.84
Upside: -34.21%
Feb 8, 2023
Maintains: Outperform
Price Target: $374 → $365
Current: $492.69
Upside: -25.92%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $111.79
Upside: -18.60%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.21
Upside: +90.40%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $10.38
Upside: -3.66%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $28.98
Upside: -65.49%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $14.51
Upside: +155.00%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $122.92
Upside: +43.18%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $8.68
Upside: +84.33%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $28.06
Upside: +60.37%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.48
Upside: +440.12%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $10.41
Upside: +293.85%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $163.11
Upside: +6.68%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $31.37
Upside: +62.58%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $15.08
Upside: -46.95%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $89.23
Upside: -0.26%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $8.28
Upside: -63.77%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $33.21
Upside: -51.82%